For citations:
Adilgereeva E.P., Nikitin A.G., Zheglo D.G., Shukhov O.A., Smirnikhina S.A., Chelysheva E.Y., Lavrov A.V., Turkina A.G., Kutsev S.I. Variants in the ASXL1 and DMNT3A genes are potential markers of the effectiveness of tyrosine kinase inhibitors therapy in chronic myeloid leukemia. Medical Genetics. 2020;19(6):88-89. (In Russ.)
Email this article 